Literature DB >> 23061781

The globalization of risk and risk perception: why we need a new model of risk communication for vaccines.

Heidi Larson1, Pauline Brocard Paterson, Ngozi Erondu.   

Abstract

Risk communication and vaccines is complex and the nature of risk perception is changing, with perceptions converging, evolving and having impacts well beyond specific geographic localities and points in time, especially when amplified through the Internet and other modes of global communication. This article examines the globalization of risk perceptions and their impacts, including the example of measles and the globalization of measles, mumps and rubella (MMR) vaccine risk perceptions, and calls for a new, more holistic model of risk assessment, risk communication and risk mitigation, embedded in an ongoing process of risk management for vaccines and immunization programmes. It envisions risk communication as an ongoing process that includes trust-building strategies hand-in-hand with operational and policy strategies needed to mitigate and manage vaccine-related risks, as well as perceptions of risk.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23061781     DOI: 10.1007/bf03261991

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  30 in total

Review 1.  Communicating science to the public: MMR vaccine and autism.

Authors:  Paul A Offit; Susan E Coffin
Journal:  Vaccine       Date:  2003-12-08       Impact factor: 3.641

2.  The complexity of social mobilization in health communication: top-down and bottom-up experiences in polio eradication.

Authors:  Rafael Obregón; Silvio Waisbord
Journal:  J Health Commun       Date:  2010

3.  A survey of UK parental attitudes to the MMR vaccine and trust in medical authority.

Authors:  Rachel Casiday; Tricia Cresswell; Deb Wilson; Catherine Panter-Brick
Journal:  Vaccine       Date:  2005-08-08       Impact factor: 3.641

Review 4.  MMR: where are we now?

Authors:  David Elliman; Helen Bedford
Journal:  Arch Dis Child       Date:  2007-07-11       Impact factor: 3.791

5.  Health interventions and the persistence of rumour: the circulation of sterility stories in African public health campaigns.

Authors:  Amy Kaler
Journal:  Soc Sci Med       Date:  2009-03-11       Impact factor: 4.634

6.  Public health response to influenza A(H1N1) as an opportunity to build public trust.

Authors:  Heidi J Larson; David L Heymann
Journal:  JAMA       Date:  2010-01-20       Impact factor: 56.272

7.  Risk perception and communication unplugged: twenty years of process.

Authors:  B Fischhoff
Journal:  Risk Anal       Date:  1995-04       Impact factor: 4.000

Review 8.  Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data.

Authors:  Sarah K Parker; Benjamin Schwartz; James Todd; Larry K Pickering
Journal:  Pediatrics       Date:  2004-09       Impact factor: 7.124

9.  Factors associated with uptake of measles, mumps, and rubella vaccine (MMR) and use of single antigen vaccines in a contemporary UK cohort: prospective cohort study.

Authors:  Anna Pearce; Catherine Law; David Elliman; Tim J Cole; Helen Bedford
Journal:  BMJ       Date:  2008-02-28

10.  What led to the Nigerian boycott of the polio vaccination campaign?

Authors:  Ayodele Samuel Jegede
Journal:  PLoS Med       Date:  2007-03       Impact factor: 11.069

View more
  12 in total

Review 1.  Epidemiology of vaccine hesitancy in the United States.

Authors:  Mariam Siddiqui; Daniel A Salmon; Saad B Omer
Journal:  Hum Vaccin Immunother       Date:  2013-11-18       Impact factor: 3.452

2.  The ISoP CommSIG for Improving Medicinal Product Risk Communication: A New Special Interest Group of the International Society of Pharmacovigilance.

Authors:  Priya Bahri; Alexander N Dodoo; Brian D Edwards; I Ralph Edwards; Irene Fermont; Ulrich Hagemann; Kenneth Hartigan-Go; Bruce Hugman; Peter G Mol
Journal:  Drug Saf       Date:  2015-07       Impact factor: 5.606

3.  Enhancing the work of the Department of Health and Human Services national vaccine program in global immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on September 12, 2013.

Authors: 
Journal:  Public Health Rep       Date:  2014       Impact factor: 2.792

4.  HHS--supporting global immunization through policies, programs, and partnerships.

Authors:  Nils Daulaire
Journal:  Public Health Rep       Date:  2014       Impact factor: 2.792

5.  Consumer reporting of adverse events following immunization (AEFI): identifying predictors of reporting an AEFI.

Authors:  Adriana Parrella; Michael Gold; Annette Braunack-Mayer; Peter Baghurst; Helen Marshall
Journal:  Hum Vaccin Immunother       Date:  2014-01-09       Impact factor: 3.452

6.  Application of real-time global media monitoring and 'derived questions' for enhancing communication by regulatory bodies: the case of human papillomavirus vaccines.

Authors:  Priya Bahri; Julianna Fogd; Daniel Morales; Xavier Kurz
Journal:  BMC Med       Date:  2017-05-02       Impact factor: 8.775

7.  Decline in HPV-vaccination uptake in Denmark - the association between HPV-related media coverage and HPV-vaccination.

Authors:  Camilla Hiul Suppli; Niels Dalum Hansen; Mette Rasmussen; Palle Valentiner-Branth; Tyra Grove Krause; Kåre Mølbak
Journal:  BMC Public Health       Date:  2018-12-10       Impact factor: 3.295

8.  Beyond fragmentary: A proposed measure for travel vaccination concerns.

Authors:  Charles Atanga Adongo; Edem Kwesi Amenumey; Akwasi Kumi-Kyereme; Eve Dubé
Journal:  Tour Manag       Date:  2020-09-13

9.  Focusing on risk communication about medicines: why now?

Authors:  Priya Bahri; Mira Harrison-Woolrych
Journal:  Drug Saf       Date:  2012-11-01       Impact factor: 5.606

10.  Yellow Fever prevention strategies awareness among HIV-infected patients in São Paulo, Brazil.

Authors:  Vivian Iida Avelino-Silva; Hilario Sousa Francelino; Esper Georges Kallás
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2014 Sep-Oct       Impact factor: 1.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.